Nina Tamirisa, MD; Heather Lin, PhD; Yu Shen, PhD; et al.
free access
JAMA Oncol. 2020;6(10):1548-1554. doi:10.1001/jamaoncol.2020.2388
This retrospective cohort study examines the association of chemotherapy with survival in elderly patients with multiple comorbidities and estrogen receptor鈥損ositive, node-positive breast cancer.
Anthony T. Nguyen, MD, PhD; Michael Luu, MPH; Jon Mallen-St Clair, MD, PhD; et al.
free access
JAMA Oncol. 2020;6(10):1555-1562. doi:10.1001/jamaoncol.2020.3172
This comparative effectiveness study compares the long-term outcomes of transoral robotic surgery with those of nonrobotic surgery in patients with early-stage oropharyngeal cancer.
-
Editorial
Robotic Surgery and Oncologic Outcomes
Yinin Hu, MD; Vivian E. Strong, MD
JAMA Oncol
Jonathan D. Schoenfeld, MD, MPH; Glenn J. Hanna, MD; Vickie Y. Jo, MD; et al.
free access
JAMA Oncol. 2020;6(10):1563-1570. doi:10.1001/jamaoncol.2020.2955
This randomized clinical trial examines the safety and efficacy of neoadjuvant nivolumab or nivolumab plus ipilimumab administered prior to surgery in patients with untreated squamous cell carcinoma of the oral cavity.
Kohei Shitara, MD; Eric Van Cutsem, MD; Yung-Jue Bang, MD; et al.
free access
JAMA Oncol. 2020;6(10):1571-1580. doi:10.1001/jamaoncol.2020.3370
This phase 3, randomized, controlled, partially blinded interventional study evaluates the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alone in patients with untreated, advanced gastric/gastroesophageal junction cancer with PD-L1 combined positive score 鈮�1.
-
Editorial
Pembrolizumab in First-line Gastric Cancer: Win, Lose, or Draw?
Elizabeth C. Smyth, MD; Markus Moehler, MD
JAMA Oncol
Mattie Salim, MD; Erik Wåhlin, MSc; Karin Dembrower, MD; et al.
free access
JAMA Oncol. 2020;6(10):1581-1588. doi:10.1001/jamaoncol.2020.3321
This case-control study of women screened at an academic hospital in Stockholm, Sweden, evaluates 3 commercially available artificial intelligence algorithms to assess whether they perform independently as well or better than radiologists in mammography screening assessment or improve the performance of radiologists.
Fenglin Liu, MD; Changming Huang, MD; Zekuan Xu, MD; et al.
free access
JAMA Oncol. 2020;6(10):1590-1597. doi:10.1001/jamaoncol.2020.3152
This randomized clinical trial compares the safety of laparoscopic total gastrectomy vs conventional open total gastrectomy in patients with clinical stage I gastric cancer.
Sara M. Tolaney, MD, MPH; Romualdo Barroso-Sousa, MD, PhD; Tanya Keenan, MD, MPH; et al.
free access
JAMA Oncol. 2020;6(10):1598-1605. doi:10.1001/jamaoncol.2020.3524
This phase 2 randomized clinical trial compares the efficacy of eribulin plus pembrolizumab vs eribulin alone in hormone receptor鈥損ositive, ERBB2-negative metastatic breast cancer.
Chen Yuan, ScD; Ana Babic, PhD, MPH; Natalia Khalaf, MD, MPH; et al.
free access
online only
JAMA Oncol. 2020;6(10):e202948. doi:10.1001/jamaoncol.2020.2948
This cohort study examines multiyear self-reported demographic, lifestyle choice, and medical history data to track weight changes, disease diagnoses, health outcomes, and other factors associated with pancreatic cancer risk among participants in 2 long-term national surveys.
Matthew R. Cooperberg, MD, MPH; Yingye Zheng, PhD; Anna V. Faino, MS; et al.
free access
online only
has audio
JAMA Oncol. 2020;6(10):e203187. doi:10.1001/jamaoncol.2020.3187
This cohort study uses data from the Canary Prostate Active Surveillance Study and University of California, San Francisco to investigate whether monitoring frequency of men with diagnosed prostate cancer can be tailored based on risk stability outcomes.
-
Podcast:
Tailoring Intensity of Surveillance for Prostate Cancer Based on Prediction of Risk Stability